Evidence map›Paper›PMID 28350844›Full record

ArticlePloS one2017

Isolation and characterization of alternatively spliced variants of the mouse sigma1 receptor gene, Sigmar1.

Ling Pan, David A Pasternak, Jin Xu, Mingming Xu, Zhigang Lu, Gavril W Pasternak, Ying-Xian Pan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. BiallelicJournal of neuromuscular diseases · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Repeated inhibition of sigma-1 receptor suppresses GABAFrontiers in molecular neuroscience · 2022
    Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ling PanDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
David A PasternakDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Jin XuDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Mingming XuDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Zhigang LuKey Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, Jianshu, China.
Gavril W PasternakDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Ying-Xian PanDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.ORCID http://orcid.org/0000-0002-4006-8304
Memorial Sloan Kettering Cancer Center · USNanjing University of Chinese Medicine · CN

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
TRAINING IN BEHAV. PHARMACOLOGY OF HUMAN DRUG DEPENDENCET32DA007242 · NIDA · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI HEIL, SARAH H, HIGGINS, STEPHEN T · 1990 to 2025
$8.2M
Synthesis &Pharmacology of Novel Opiates and SystemsR01DA006241 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAN, YING-XIAN · 1990 to 2018
$6.4M
PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPESR01DA007242 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAN, YING-XIAN · 1991 to 2022
$6.0M
Characterizing exon 11 promoter of the mu opioid receptor gene, OPRMR01DA013997 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAN, YING-XIAN · 2002 to 2012
$3.3M
PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPESR37DA007242 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PASTERNAK, GAVRIL W · 1996 to 2004
$1.5M
Exploring functions of mu opioid receptor carboxyl termini by gene targetingR21DA029244 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2010 to 2011
$522k
Exploring function of mu opioid receptor splice variants in rat by gene targetingR21DA040858 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2016 to 2017
$471k
NCI NIH HHS P30 CA008748NIDA NIH HHS R01 DA006241NIDA NIH HHS R01 DA007242NIDA NIH HHS R01 DA013997NIDA NIH HHS R21 DA029244NIDA NIH HHS R21 DA040858NIDA NIH HHS R37 DA007242NIDA NIH HHS T32 DA007242
6 · The paper itself

Abstract

The sigma1 receptor acts as a chaperone at the endoplasmic reticulum, associates with multiple proteins in various cellular systems, and involves in a number of diseases, such as addiction, pain, cancer and psychiatric disorders. The sigma1 receptor is encoded by the single copy SIGMAR1 gene. The current study identifies five alternatively spliced variants of the mouse sigma1 receptor gene using a polymerase chain reaction cloning approach. All the splice variants are generated by exon skipping or alternative 3' or 5' splicing, producing the truncated sigma1 receptor. Similar alternative splicing has been observed in the human SIGMAR1 gene based on the molecular cloning or genome sequence prediction, suggesting conservation of alternative splicing of SIGMAR1 gene. Using quantitative polymerase chain reactions, we demonstrate differential expression of several splice variants in mouse tissues and brain regions. When expressed in HEK293 cells, all the splice variants fail to bind sigma ligands, implicating that each truncated region in these splice variants is important for ligand binding. However, co-immunoprecipitation (Co-IP) study in HEK293 cells co-transfected with tagged constructs reveals that all the splice variants maintain their ability to physically associate with a mu opioid receptor (mMOR-1), providing useful information to correlate the motifs/sequences necessary for their physical association. Furthermore, a competition Co-IP study showed that all the variants can disrupt in a dose-dependent manner the dimerization of the original sigma1 receptor with mMOR-1, suggesting a potential dominant negative function and providing significant insights into their function.

Indexed as

Alternative SplicingAmino Acid SequenceAnimalsCloning, MolecularExonsGene Expression ProfilingHEK293 CellsHumansMaleMice, Inbred C57BLModels, GeneticPolymerase Chain ReactionProtein BindingProtein IsoformsReceptors, sigmaSequence Homology, Amino AcidProtein IsoformsReceptors, sigmaSigma-1 Receptor

Identifiers

PMID28350844
PMCPMC5370144
OpenAlexW2599923511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.